Clinical Trials Browser

Active not recruiting × Lung Neoplasms × tremelimumab × Clear all

NCT03923270 2026-04-01

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Phase 1 Active not recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT03703297 2025-11-21

ADRIATIC

Phase 3 Active not recruiting

730 enrolled 19 charts 1 FDA

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma